Expert Opinion on Drug Safety, Volume 23, Issue 3 (2024)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Drug Safety, Volume 23, Issue 3 (2024)

See all volumes and issues
Volume 23, 2024 Vol 22, 2023 Vol 21, 2022 Vol 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002
Download citations Download PDFs Download issue

Meta-analysis

Review Article
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis
Di Wu, Jianrong He, Ping Shi, Zirong Wang, Min Liu & Anchang Liu
Pages: 269-276
Published online: 24 Oct 2023
AbstractforQuality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis | Full Text | References | PDF (5.3 MB) | EPUB | Supplemental
  • 85 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling
Ling Wang, Jie Cao, Jian Tao & Yan Liang
Pages: 277-286
Published online: 11 Oct 2023
AbstractforSTMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling | Full Text | References | PDF (6.3 MB) | EPUB
  • 90 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study
Xin Lai, Qing Wan, Shou-Feng Jiao, Xiao-Chun Sun, Jin-Fang Hu & Hong-Wei Peng
Pages: 287-296
Published online: 29 Aug 2023
AbstractforCardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study | Full Text | References | PDF (2.6 MB) | EPUB
  • 226 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
Bing Cao, Shanshan Gu, Zhisen Shen, Yuna Zhang, Yiming Shen & Hang Chen
Pages: 297-303
Published online: 24 Aug 2023
AbstractforEvaluating Ubrogepant-related adverse events using the FDA adverse event reporting system | Full Text | References | PDF (699.9 KB) | EPUB | Supplemental
  • 120 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS
Yu Sun, Tao Xu, Suyan Zhu & Hongbin Xu
Pages: 305-311
Published online: 16 Oct 2023
AbstractforCharacteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS | Full Text | References | PDF (234.1 KB) | EPUB | Supplemental
  • 152 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
Tingxi Wu, Yanfeng Shi, Bin Zhu, Dandan Li, Zhe Li, Zhigang Zhao & Yang Zhang
Pages: 313-321
Published online: 01 Sep 2023
AbstractforPregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 335 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
C. Ouaddouh, J.W. Duijster, T. Lieber & F.P.A.M. van Hunsel
Pages: 323-331
Published online: 11 Oct 2023
AbstractforThe role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 103 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data
Hui Yang, Zhexin Ding & Zhuoling An
Pages: 333-338
Published online: 25 Aug 2023
AbstractforUrinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data | Full Text | References | PDF (592.9 KB) | EPUB
  • 110 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Data mining and analysis of the adverse events derived signals of 4 gadolinium-based contrast agents based on the US Food and drug administration adverse event reporting system
Lu Wang, Yinglin Wang & Quan Zhao
Pages: 339-352
Published online: 24 Oct 2023
AbstractforData mining and analysis of the adverse events derived signals of 4 gadolinium-based contrast agents based on the US Food and drug administration adverse event reporting system | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 187 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)
Shu-Peng Zou, Hai-Yun Yang, Mengling Ouyang, Qian Cheng, Xuan Shi & Ming-Hui Sun
Pages: 353-362
Published online: 29 Aug 2023
AbstractforPost-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS) | Full Text | References | PDF (2.4 MB) | EPUB | Supplemental
  • 316 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
A real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System
Ruishan Zhou, Peiwen Lu, Mingxiu He, Junheng Chen, Yiyang Shi, Fangfang Han & Yongming Cai
Pages: 363-371
Published online: 04 Sep 2023
AbstractforA real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System | Full Text | References | PDF (922.2 KB) | EPUB | Supplemental
  • 246 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database
Haixia Cai, Beixi Jia, Zhonghua Fu, Boya Chen, Yinping Liu & Shujuan Zhao
Pages: 373-383
Published online: 27 Oct 2023
AbstractforReal-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database | Full Text | References | PDF (785.7 KB) | EPUB | Supplemental
  • 145 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database
Yunfei Li, Haiyun Yang, Yuan Gao & Weimin He
Pages: 385-391
Published online: 28 Aug 2023
AbstractforOcular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database | Full Text | References | PDF (433.5 KB) | EPUB | Supplemental
  • 91 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles